• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Uncovering 3 Penny Stocks With Market Caps Under $700M

    Simply Wall St·04/08/2026 17:05:16
    Listen to the news

    The market has climbed 1.2% in the last 7 days and is up 33% over the last 12 months, with earnings forecast to grow by 16% annually. Investing in penny stocks can still open doors to growth opportunities, typically in smaller or newer companies that come backed by strong financial health. Let's explore several penny stocks that could pair balance sheet strength with long-term potential.

    Top 10 Penny Stocks In The United States

    Name Share Price Market Cap Rewards & Risks
    ATRenew (RERE) $4.38 $998.2M ✅ 4 ⚠️ 0 View Analysis >
    LexinFintech Holdings (LX) $2.15 $385.32M ✅ 3 ⚠️ 2 View Analysis >
    Tuya (TUYA) $2.33 $1.42B ✅ 4 ⚠️ 1 View Analysis >
    FinVolution Group (FINV) $4.95 $1.29B ✅ 4 ⚠️ 1 View Analysis >
    Tuniu (TOUR) $0.63 $84.58M ✅ 2 ⚠️ 2 View Analysis >
    Information Services Group (III) $3.11 $188.31M ✅ 4 ⚠️ 1 View Analysis >
    Golden Growers Cooperative (GGRO.U) $5.00 $77.45M ✅ 2 ⚠️ 5 View Analysis >
    Niagen Bioscience (NAGE) $4.47 $358.71M ✅ 3 ⚠️ 1 View Analysis >
    LifeVantage (LFVN) $4.04 $53.52M ✅ 4 ⚠️ 3 View Analysis >
    SIGA Technologies (SIGA) $7.80 $372.55M ✅ 2 ⚠️ 1 View Analysis >

    Click here to see the full list of 360 stocks from our US Penny Stocks screener.

    Let's take a closer look at a couple of our picks from the screened companies.

    Spero Therapeutics (SPRO)

    Simply Wall St Financial Health Rating: ★★★★★★

    Overview: Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for multi-drug resistant bacterial infections and rare diseases in the United States, with a market cap of $151.10 million.

    Operations: The company's revenue is primarily derived from its novel treatments for multi-drug resistant bacterial infections, totaling $66.80 million.

    Market Cap: $151.1M

    Spero Therapeutics has recently transitioned to profitability, reporting a net income of US$31.52 million for Q4 2025, a significant improvement from the previous year's loss. With no debt and short-term assets of US$67.3 million exceeding liabilities, its financial position is solid. The company's revenue for 2025 was US$66.8 million, driven by innovative treatments for multi-drug resistant infections. Despite limited management experience with an average tenure of 1.3 years, the board's seasoned expertise provides stability. Spero's price-to-earnings ratio of 18x suggests it may offer good value relative to the broader market average of 18.7x.

    SPRO Debt to Equity History and Analysis as at Apr 2026
    SPRO Debt to Equity History and Analysis as at Apr 2026

    Riskified (RSKD)

    Simply Wall St Financial Health Rating: ★★★★★★

    Overview: Riskified Ltd. develops an e-commerce risk intelligence platform for online merchants globally, with a market cap of approximately $600.23 million.

    Operations: The company's revenue is derived from its Security Software & Services segment, totaling $344.64 million.

    Market Cap: $600.23M

    Riskified Ltd., with a market cap of US$600.23 million, operates in the e-commerce risk intelligence space and has shown resilience despite being unprofitable. The company maintains a stable cash runway exceeding three years due to positive free cash flow, while its short-term assets significantly surpass liabilities. Recent partnerships, such as with Outpayce from Amadeus and Radial, enhance Riskified's AI-driven fraud prevention capabilities for travel and e-commerce sectors, potentially bolstering revenue predictability and operational efficiency. Additionally, the company's strategic share repurchase program underscores confidence in its financial health amidst ongoing expansion efforts.

    RSKD Financial Position Analysis as at Apr 2026
    RSKD Financial Position Analysis as at Apr 2026

    Elite Pharmaceuticals (ELTP)

    Simply Wall St Financial Health Rating: ★★★★★★

    Overview: Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and selling oral controlled-release and generic pharmaceuticals with a market cap of $404.20 million.

    Operations: The company's revenue is primarily derived from its Abbreviated New Drug Applications (ANDA) segment, amounting to $140.12 million.

    Market Cap: $404.2M

    Elite Pharmaceuticals has demonstrated significant financial improvement, with revenue for the third quarter reaching US$31.59 million, a substantial increase from the previous year's US$14.36 million. The company has transitioned to profitability, reporting a net income of US$18.59 million compared to a net loss of US$10.89 million last year. Elite's short-term assets of US$96.8 million comfortably cover both its short-term and long-term liabilities, indicating strong financial stability for a penny stock. Additionally, Elite's operating cash flow adequately covers its debt obligations and its seasoned management team further supports operational resilience in this competitive sector.

    ELTP Debt to Equity History and Analysis as at Apr 2026
    ELTP Debt to Equity History and Analysis as at Apr 2026

    Make It Happen

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.